IPO Calendar
Lead Manager
- J P Morgan Chase (515)
- Goldman Sachs (492)
- Morgan Stanley (445)
- Bank of America Merrill Lynch (374)
- Citigroup (236)
- Jefferies (223)
- Credit Suisse (180)
- Barclays (158)
- Cowen and Company (147)
- Deutsche Bank (85)
- Leerink Partners (73)
- Piper Jaffray (70)
- Stifel (67)
- UBS Investment Bank (56)
- Evercore (55)
- RBC Capital (53)
- BMO Capital (52)
- Wells Fargo (48)
- Piper Sandler (43)
- Revere Securities (42)
More +
IPO - Pricing (8)
Leerink Partners
| UnderWriters* | |||||||||||
| Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | 89bio Inc. | Health-Care | 16 | 5 | BAML | LRNK | RBC | 4.6% | 30% | ||
| Nov 7 | Centogene B.V. | Health-Care | 14 | 4 | LRNK | EVCR | 23.2% | -10.8% | |||
| Jul 25 | Castle Bioscien | Health-Care | 16 | 4 | LRNK | BARD | 53.9% | 33.8% | |||
| Jul 18 | Fulcrum Therape | Health-Care | 16 | 4 | MS | BAML | LRNK | 27.6% | -15.6% | ||
| May 7 | Trevi Therapeut | NA | 10 | 5 | LRNK | Stifel | BMO | 24.9% | -21.1% | ||
| Apr 17 | Turning Point T | NA | 18 | 9 | GS | LRNK | WLFG | 34.2% | 60.6% | ||
| Feb 8 | Harpoon Therape | NA | 14 | 5 | CITI | LRNK | 24.3% | -3.6% | |||
| Feb 8 | Gossamer Bio In | NA | 16 | 17 | BAML | LRNK | BRCL | 34.2% | 12.1% | ||
*
Lead manager or one of top three managers in an underwriting team.